April 2015

Curriculum Vitae

Professor Charles SwantonMB PhD BSc FRCP

Chair, Personalised Cancer Medicine, University College London

Co-Director CR-UK UCL/Manchester Lung Cancer Centre of Excellence

http://www.cruklungcentre.org

Francis Crick Institute Senior Group LeaderTranslational Cancer Therapeutics Laboratory

http://www.crick.ac.uk/research/a-z-researchers/researchers-p-s/charles-swanton/

Personal Details.

Name Robert Charles SwantonDOB 24th February 1972Address 7 Lindisfarne Road, London SW20 0NWNationality BritishEmail charles.swanton@cancer.org.ukGMC 4637055MPS 273194RCP 106772Indemnity Medical Protection Society Number 273194Telephone Home 020 8947 2981 Work 0207 352 8171

Mobile 07956 445302

Education

1991-1993 Pre-clinical medicine, St.Bartholomew’s and the Royal London Medical School.

1993-1999 MB PhD Programme, University College London Medical School.

1995-1998 PhD, Imperial Cancer Research Fund, 44 Lincoln’s Inn Fields, London.

Qualifications

BSc 1995 Cellular Pathology, UCL.First Class Honours.

PhD 1998 Imperial Cancer Research Fund, Lincoln’s Inn FieldsViral Cyclin Evasion of Cell Cycle Control Mechanisms (1998).PhD Thesis University of London.Pontecorvo Thesis Prize

MBBS 1999 University College London Medical Schools.

MRCP 2002.

PG Cert Oncology 2007

CCT PMETB 2008 Completion of Medical Oncology Training

FSB 2008 Fellow of the Society of Biology

FRCP 2011 Fellow of the Royal College of Physicians

FEACS Fellow of the European Academy of Cancer Sciences 2013

Academic Prizes, Visiting Professorships and Esteem Factors

MBPhD Bursary, 1995

Oncology Prize UCLMS 1997

Biochemistry Prize UCLMS 1997

UCL Postgraduate Research Prize 1998

Pontecorvo ICRF PhD Thesis Award 1999

Distinction, Pathology Finals, 1999.

Merit General Medicine, 1999.

Grand Round Prize in General Medicine, 2002, Newham General Hospital.

San Antonio Breast Cancer Symposium : Basic Science Scholar 2006

Emerging Leader in Oncology Prize: Pfizer 2010

Breast Cancer Research Foundation Fellowship 2012

Prostate Cancer Foundation Challenge Award 2012

Paper titled “Intratumour heterogeneity and branched evolution revealed by multiregion sequencing” ranked 1st in Faculty of 1000 May 2012

Thomson-Reuters Science watch WebofScience as of October 4, 2012, “Intratumour heterogeneity and branched evolution revealed by multiregion sequencing” displayed a higher bimonthly citation increase than any other paper of comparable age and type in its field.

Graham Bull prize in Clinical Science,Royal College of Physicians 2013

Goulstonian Lecture 2014, Royal College of Physicians

Top Teacher Award UCL Medical School 2012/13

Jeremy Jass Prize for Research Excellence in Pathology (2014)

CRUK London Research Institute Milestone achievement: Swanton laboratory and Tumour Heterogeneity reviewed as final milestonehttp://www.london-research-institute.org.uk/sites/default/files/milestone_21.pdf

Stand Up 2 Cancer Laura Ziskin Translational Cancer Research Prize (2015)

GlaxoSmithklinePrize (2016), Biochemical Societyin recognition of distinguished research leading to new advances in medical science.

Invited Named and Prize Lectureships

Geoffrey Beene Symposium   Memorial Sloan-Kettering Cancer Center “Cancer Heterogeneity” November 2012

Lelund Chung LectureBasic Urologic Research Meeting, Tennessee Nov 14-17th 2013

The Ruth Sager Memorial Symposium: Cancer Heterogeneity AACR 2013

Goulstonian Lecture February 2014, Royal College of Physicians

D. Wayne Calloway Lectureship in Prostate Cancer Memorial Sloan Kettering Cancer Centre February 2014

Visiting Professor Cedars Sinai Hospital 2012

Invited Visiting Professor February 2015, 100th anniversary of the Daniel den Hoed Cancer Centre, Erasmus MC Cancer Institute, Erasmus University Medical Centre Rotterdam

Membership of Professional Bodies

Fellow of the Royal College of PhysiciansFellow of the European Academy of Cancer SciencesMember of AACR membership number 229907Executive board committee member of the British Association for Cancer Research (BACR)Member of EACR membership number 19043Member of ESMOMember of IASLC membership number 415814Board member of of UCL Partners Academic Health Sciences Centre

Employment

1999-2000

Surgical House Officer Chase Farm Hospital. General Surgery, Breast Surgery and Urology. Mr Bolton, Mr Jaffe, Mr Khan, Mr Copland.

2000 Medical House Officer UCL Hospitals. General Medicine. Professor Fine, Dr. Stewart and Dr. Cohen.

2000-1

Senior House Officer in Neurology. National Hospital for Neurology and Neurosurgery, Queen Square London. NeurogeneticsDr. Wood, General Neurology Dr.Merry, Cognitive and

Dementia Professor Rossor, Neuropsychiatry Professor Trimble and Professor Ron.

2001 Senior House Officer in Cardiology. Hammersmith Hospital, Cardiology and Clinical Pharmacology. Professor Martin Wilkins.

2001-2

Senior House Officer in Oncology. Royal Marsden Hospital, Fulham Road. Medical and Clinical Oncology. Professor Martin Gore, Dr.T.Eisen, Dr. K. Harrington and Dr. C. Nutting.Ovarian, Renal, Melanoma and Head and Neck Cancers

2002 Senior House Officer in General Medicine and Endocrinology. Newham General Hospital, Glen Road, Newham. Dr. W. Drake, Dr. C. Gayle, Dr. S. Vijay.

2002-3

Specialist Registrar Medical Oncology. Royal Surrey County Hospital NHS Trust. Dr. G. Middleton 7 months: Lung cancer, Upper and lower gastro-intestinal tumours and Dr.S.Houston 5 months: Breast, Renal and Melanoma.

2003-4

Specialist Registrar Medical Oncology. Breast Unit, Royal Marsden Hospital NHS Trust, Dr S.Johnston and Professor I. Smith: 7 Months Metastatic Breast Cancer.

2004 Specialist Registrar Medical Oncology. Lung Unit, Royal Marsden Hospital NHS Trust. Dr Tim Eisen.

2004 Specialist Registrar Medical Oncology. Lymphoma and Sarcoma Units, Royal Marsden Hospital NHS Trust, Prof D. Cunningham and Prof I. Judson.

2004-8

CR-UK Clinician Scientist Fellowship. Julian Downward Signal Transduction Laboratory, CR-UK London Research Institute, 44 Lincoln’s Inn Fields, London WC2A 3PX.

2005 Specialist Registrar Medical Oncology Lymphoma and Sarcoma Units Royal Marsden Hospital NHS Trust, Sarcoma and Lymphoma Unit, Prof D. Cunningham and Prof I. Judson.

2006 Specialist Registrar Medical Oncology. GI Unit ,Royal Marsden Hospital NHS Trust, Prof D. Cunningham.

2007 Specialist Registrar Medical Oncology. Gynae Unit, Royal Marsden Hospital NHS Trust, Prof M.Gore.

Jan-July 2008

Specialist Registrar Medical Oncology. Breast Unit, Royal Marsden Hospital NHS Trust, Prof Smith and Dr Johnston.

May 2008 –2011

MRC/CRUK Senior Clinical FellowshipGroup Leader,Translational Cancer Therapeutics Laboratory,CR-UK London Research Institute Laboratory Websitehttp://science.cancerresearchuk.org/research/loc/london/lifch/swantonc/

Consultant Medical OncologistRoyal Marsden Hospital, Department of Medicine, Breast and Drug Development Unit, Downs Road,Sutton

May 2008 - 2014

MRC/CRUK Senior Clinical Fellowship

Present

Group Leader,Translational Cancer Therapeutics Laboratory,CR-UK London Research Institute Laboratory Websitehttp://science.cancerresearchuk.org/research/loc/london/lifch/swantonc/

July 2011 Chair, Personalised Cancer Medicine, University College London Cancer Institute, Huntley Street, London

August 2013 -

CRUK Senior Group Leader

Present Translational Cancer Therapeutics Laboratory,

CR-UK London Research Institute Laboratory Websitehttp://science.cancerresearchuk.org/research/loc/london/lifch/swantonc/

Director CR-UK UCL/Manchester Lung Cancer Centre,University College London Cancer Institute, Huntley Street, London

Publications

PhD Thesis.

Swanton C, Viral Cyclin Evasion of Cell Cycle Control Mechanisms (1998). PhD Thesis University of London.

Peer-reviewed.

1) Swanton C, Mann DJ, Fleckenstein B, Neipel F, Peters G, Jones N (1997). Herpes Viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature 390(6656) p184-7

2) O’Neil D, Swanton C, Jones A, Medd PG, Rayment N, Chain B, IFN-gamma down regulates MHC expression and antigen processing in a human B cell line. Journal of Immunology (1999) 162(2) p791-8

3) Swanton C, Card GL, Mann DJ, Mcdonald N, Jones N. Overcoming Inhibitions: subversion of CKI function by viral cyclins. (1999) Trends in Biochemical Sciences 24(3) p116-120

4) Mann DJ, Child ES, Swanton C, Laman H, Jones N. (1999). Modulation of p27(Kip1) levels by cyclin encoded by Kaposi’s sarcoma associated herpesvirus. EMBOJ 18(3) p654-663

5) Swanton C, Jones N. (2001). Subversion of the mammalian cell cycle by viral gene products.International Journal of Experimental Pathology

6) Swanton C (2004) Cell-cycle targeted therapies. Lancet Oncology Jan;5(1):27-36. Review.

7) Swanton C, Nicke B, Downward J. (2004) RNA interference, DNA methylation, and gene silencing: a bright future for cancer therapy?Lancet Oncology 2004 Nov;5(11):653-4.

8)Swanton C. and Downward J. (2005) Small and Interfering :RNA interference Technology : From Basic Science to Drug Development. Lancet Oncology July p457 6(7).

9) Yau T, Swanton C. et al. (2006) Brain as a sanctuary site for early relapse in patients with advanced breast cancer treated with trastuzumab. ActaOncol. 45(2):196-201

10) Swanton C., Futreal A., Eisen T. (2006) Her2-Targeted therapies in Non-Small Cell Lung Cancer Clin Cancer Research 2006 Jul 15;12(14 Pt 2):4377s-4383s

11) Swanton C., Tomlinson I., Downward J. (2006) Chromosomal Instability, Colorectal Cancer and Taxane Resistance.Cell Cycle Apr 17;5(8)

12) Jones R.L., Swanton C., Ewer M.S, (2006) AnthracyclineCardiotoxicity. Expert Opinion in Drug Safety 5 (6) p791-809.

13) Swanton C.*, Marani M.*, Pardo O., Warne P., Elustondo F., Sahai E., Ahmed A., Brenton J., Temple J., Downward J., Nicke B. (2007) Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell (6) p498-512. * These authors contributed equally to the work.

14) Swanton C., Nicke B., Marani M., Kelly G., Downward J., Initiation of high frequency multi-drug resistance following kinase targeting by siRNAs. (2007) Cell Cycle Aug 15; 6(16)

15) Ahmed A., Mills A., Ibrahim A., Temple J., Blenkiron C., Vias M., Massie C., Lyer G., McGeoch A., Crawford R., Nicke B., Downward J., Swanton C., Bell S., Earl H., Laskey R., Caldas C. ,Brenton J. (2007) The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell. Dec 6;12(6):514-527.

16) Swanton C*., Downward J*. (2008) Unravelling the complexity of endocrine resistance in breast cancer by functional genomics. Cancer Cell Feb;13(2):83-5 * Joint corresponding author

17) Harrison M., Swanton C.* (2008) Epothilones and New Analogues of the Microtubule Modulators in Taxane Resistant Disease. Expert Review of Investigational Drugs 17(4):523-46. *corresponding author

18) Olmos D. *, Swanton C.*, De Bono J.,Targeting Polo-like kinase: Learning too little too late. (2008) Dec 1;26(34):5497-9 Journal of Clinical Oncology. * Joint first author.

19) Lee A., East P., Pepper S., Nicke B., Szallasi Z., Eklund A., Downward J.* and Swanton C*.(2008) Concordance of exon array and real time PCR assessment of gene expression following cancer cell cytotoxic drug exposure.Cell Cycle 7:24 1-2.* corresponding authors

20)Swanton C*.,Szallasi Z, Brenton J. and Downward J., Functional Genomic Analysis of Drug Sensitivity Pathways to Guide Adjuvant Strategies in Breast Cancer (2008) .Breast Cancer Res. Oct 31;10(5):214 *corresponding author

21) Lee A., Swanton C. *, (2009) Functional Genomic Analysis of Drug Sensitivity Pathways. Expert Reviews in Molecular Medicine. 2009 May 21;11:e15.*corresponding author

22) Swanton C., Caldas C., (2009) Update on the Molecular Classification of Solid Tumours. British Journal of Cancer May 19;100(10):1517-22

23) Swanton C, Nicke B, Schuett M, Eklund AC, Ng C, Li Q, Hardcastle T, Lee A, Roy R, East P, Kschischo M, Endesfelder D, Wylie P, Kim SN, Chen JG, Howell M, Ried T, Habermann JK, Auer G, Brenton JD, Szallasi Z, Downward J.(2009)Chromosomal Instability determines taxane response. ProcNatlAcadSci U S A May 26;106(21):8671-6.

24) Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D.Genetic prognostic and predictive markers in colorectal cancer. (2009) Nature Reviews Cancer Jul;9(7):489-99

25) Larkin JM, Kipps EL, Powell CJ,Swanton C (2009) Systemic therapy for advanced renal cell carcinoma. Therapeutic Advances in Medical Oncology Vol. 1, No. 1, 15-27

26) McClelland S, Burrell R, SwantonC* (2009) Chromosomal Instability: A Composite Phenotype That Determines Drug Resistance Cell Cycle 8(20):3262-6 *Corresponding author

27)Swanton C* and Burrell R (2009) Advances in personalised therapeutics in Non-Small Cell Lung Cancer: 4q12 amplification, PDGFRA oncogene addiction and Sunitinib sensitivity. Cancer Biology and Therapy 24;8(21) *Corresponding author

28) Tejpar S., Bertagnolli M., Bosman F., Lenz H-J., Garraway L., Waldman F., Warren R., Bild A., Collins-Brennan D., Hahn H., Harkin P., Kennedy R., Ilyas M., Morreau H., Proutski V., SwantonC., Tomlinson I., Delorenzi M., Fiocca R., Van Cutsem E., Roth A. (2010)Prognostic and predictive biomarkers in resected colorectal cancer - current status and future perspectives: integrating genomics into biomarker discovery; an expert opinion. Oncologist 15(4):390-404.

29) McKeen H., Byrne C., JitheshP.V., DonleyC., ValentineA., YakkundiA., Swanton C., McCarthyH.O., HirstD.G., Robson T. (2010) FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy Cancer Research 1;70(3):1090-100

30) Evaluation of an RNA interference screen-derived mitotic and ceramide pathway metagene in paclitaxel-treated

primary ER-/PR-/ERBB2- breast cancer: a retrospective analysis of five clinical trials.Juul N., Eklund A., Li Q., Burrell R.A., Valero V., Andreopoulou E., Esteva F.J., Symmans W.F, Desmedt C., Haibe-Kains B., Sotiriou C., Pusztai L., Szallasi Z.and Swanton C*. (2010) Lancet Oncology 11(4):358-65 *Corresponding author

31) Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference.(2010)Daniel Tan, Marco Gerlinger, Bin Teh and Charles Swanton* Eur J Cancer. Aug;46(12):2166-2177 *Corresponding author

32) Breast cancer in the post-genomic era. Swanton C (2010) British Journal of Cancer 29;103(1):155

33) Predictive molecular markers of response to EGFR/HER2 targeted therapy Invited Review Barton S., Starling N., Swanton C* (2010) Invited review Current Cancer Drug Targets Aug 19th

*Corresponding author

34) A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit,Brunetto A., Kaye S.B., De Bono J., Allen M., Johnston S.R.D., Swanton C. (2010) British Journal of CancerAug 24;103(5):607-12

35) Targeting Chromosomal Instability and Tumour Heterogeneity in HER2 Positive Breast CancerRebecca Burrell, Stephen Johnston, Jorge Reis-Filho, NicolaiJuul, ZoltanSzallasi, Charles Swanton*

(2010) Journal of Cellular Biochemistry Nov 1;111(4):782-90*Corresponding author

36) From genomic landscapes to personalized cancer management- is there a roadmap? Charles Swanton and Carlos Caldas (2010)Ann N Y Acad Sci. 2010 Oct;12 10(1):34-44

37) Predictive Biomarker Discovery through the Parallel Integration of Clinical Trial and Functional Genomics Datasets Charles Swanton*, James M.G. Larkin, Marco Gerlinger, Aron C. Eklund, Michael Howell, Gordon Stamp, Julian Downward, Martin Gore, P. Andrew Futreal, Bernard Escudier, Fabrice Andre, Laurence Albiges, Benoit Beuselinck, StephaneOudard, Jens Hoffmann, BalazsGyorffy, Chris Torrance, Karen A. Boehme, HansjuergenVolkmer, LuisellaToschi, Barbara Nicke, Marlene Beck and ZoltanSzallasi(2010)Genome Medicine Aug 11;2(8):53.*Corresponding author

38) How Darwinian Models inform Therapeutic Failure through Clonal Heterogeneity in Cancer Medicine (2010) Marco Gerlinger

and Charles Swanton* British Journal of Cancer Oct 12;103(8):1139-43 * Corresponding author

39)Minimising Immunohistochemical False Negative ER Classification Using a Complementary 23 Gene Expression Signature of ER status(2010) Qiyuan Li, Aron C. Eklund, Nicolai Juul, Benjamin Haibe-Kains, Christopher T. Workman, Andrea L. Richardson, ZoltanSzallasi* andCharles Swanton* * Joint Corresponding authors PLOS One 2010 Dec 1;5(12):e15031.

40)Breast Cancer Genome Heterogeneity: A Challenge to Personalised Medicine?Charles Swanton, Rebecca Burrell and P. Andrew Futreal (2011) Breast Cancer Research Editorial Feb 1;13(1):104

41) Chromosomal Instability Confers Intrinsic Multi-Drug Resistance Alvin J X Lee, David Endesfelder, Andrew J Rowan, Axel Walther, Nicolai J Birkbak, P Andrew Futreal, Julian Downward, ZoltanSzallasi, Ian P M Tomlinson,MaikKschischoand Charles Swanton* (2011) Cancer Research Mar 1;71(5):1858-70 *Corresponding author.

42) Paradoxical Relationship Between Chromosomal Instability and Survival Outcome in Cancer.Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, Tan P, Tan IB, Richardson AL, Szallasi Z*, Swanton C*(2011) *Joint Corresponding author Cancer Research. May 15;71(10):3447-3452.

43)KRAS 3´-UTR variants and stratification of breast-cancer risk.Kumar M and Swanton C* (2011) Invited Commentary Lancet OncologyApr;12(4):318-9 *Corresponding author

44) Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action.Larkin J, Swanton C, Pickering L.Expert Rev Anticancer Ther. 2011 Apr;11(4):639-49.

45)A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high riskhistopathological variables.Endesfelder D., McGranahan N., Birkbak N., Szallasi Z., Kschischo M., Graham T* and Swanton C* *Joint Corresponding author Oncotarget 2011 Jul;2(7):529-37

46)Integrating Molecular Mechanisms and Clinical Evidence in the Management of Trastuzumab Resistant or Refractory HER2 positive Metastatic Breast CancerWong H, Leung R, Kwong A, Chiu J, Liang R, Swanton C* and Yau T Oncologist(2011)16(11):1535-46, *Corresponding author

47)Relationship of Extreme Chromosomal Instability with Long-term Survival in a Retrospective Analysis of Primary Breast Cancer. Roylance R., Endesfelder D., Gorman P., Burrell R.A., Sander J., Tomlinson I., Hanby A.M., Speirs V., Richardson A., Birkbak N., Eklund A.C., Downward J., Kschischo M., Szallasi Z., Swanton C*.Cancer Epidemiol Biomarkers Prev.(2011)Oct;20(10):2183-94. *Corresponding author

48)Recent Developments in the Stratification of Treatments for Metastatic Breast Cancer Sarah Barton and Charles Swanton.Drugs(2011) Nov 12;71(16):2099-113

49) Promoting predictive, preventive and personalized medicine: European event of global importance. Golubnitschaja O., Swanton C.,Danesi R., Costigliola V. EPMA Journal(2011) 2 131-136

50)Whole genome RNA expression profiling of endoscopic biliary brushings provides data suitable for biomarker discovery in cholangiocarcinoma. Michael Huw Chapman, RobertTidswell, James S Dooley, Neomal S Sandanayake, VirginieCerec, MaeshaDeheragoda, Alvin J Lee, Charles Swanton, FaustoAndreola, Stephen P Pereira Journal of Hepatology 2012 Apr;56(4):877-85.

51)Tumour Heterogeneity and Drug Resistance: Personalising Cancer Medicine through Functional Genomics Alvin Lee and Charles Swanton Invited Review manuscript BiochemPharmacol. 201215;83(8):1013-20.

52) Unlocking Pandora's Box: Personalising Cancer Cell Death in Non-Small Cell Lung Cancer Dean Fennell and Charles Swanton in press EPMA Journal 2012 Jun 18;3(1):6.

53) Histone and Chromatin Regulation in Renal Cell Carcinoma: Opportunities for therapeutic intervention?  James Larkin, Xin Yi Goh, Marcus Vetter, Lisa Pickering, Andrew Futreal, and Charles SwantonNature Reviews Urology 2012 Jan 17;9(3):147-55

54)  Delivering Preventive, Predictive and Personalised Cancer Medicine for Renal Cell Carcinoma: The challenge of tumour heterogeneity  Rosalie Fisher, James Larkin and Charles Swanton in pressEPMA Journal in press 2012    

55) CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction. Lee A., Roylance R., Sander J., Gorman P., Endesfelder D., Kschischo M., Jones N.P., East P., Nicke B., Spassieva S., Obeid L., Birkbak N., Szalassi Z., Mcknight N.C.,

Rowan A., Speirs V., Hanby A., Downward J., Swanton C*. Journal of Pathology 2012 Feb;226(3):482-94

56) Biomarkers for the personalization of prostate cancer therapy Tim Yap, Charles Swanton and Johann De Bono, in press EPMA Journal in press 2012.

57) A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor negative and positive breast cancers Natrajan R, Mackay A, Lambros MB, Weigelt B, Wilkerson PM, Manie E, Grigoriadis A, A'hern R, van der Groep P, Kozarewa I, Popova T, Mariani O, Turaljic S, Furney SJ, Marais R, Rodruigues DN, Flora AC, Wai P, Pawar V, McDade S, Carroll J, Stoppa-Lyonnet D, Green AR, Ellis IO, Swanton C, van Diest P, Delattre O, Lord CJ, Foulkes WD, Vincent-Salomon A, Ashworth A, Henri Stern M, Reis-Filho JS. Journal of Pathology (2012) May;227(1):29-41.

58) Genome-wide RNA Interference Analysis of Renal Carcinoma Survival Regulators Identifies MCT4 as a Warburg Effect Metabolic Target.Marco Gerlinger, Claudio R. Santos, Bradley Spencer-Dene, Pierre Martinez, David Endesfelder, Rebecca A. Burrell1, Marcus Vetter, Ming Jiang, Rebecca Saunders, Gavin Kelly, Nathalie Rioux-Leclercq, Gordon Stamp, Jean Jacques Patard, James Larkin, Michael Howell, Charles SwantonJournal of Pathology (2012) Jun;227(2):146-56

59)Intratumor Heterogeneity: Seeing the Wood for the Trees. Timothy A Yap, Marco Gerlinger, P. Andrew Futreal, LajosPusztai and Charles Swanton*Corresponding author Science Translation Medicine March 28th 2012 Mar 28;4(127):.

60)Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald N, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund A, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Charles Swanton* *corresponding author. New England Journal of Medicine Mar 8;366(10):883-92.2012.

Accompanying News and Views: Tumor Heterogeneity and personalised medicine Longo DL N Engl J Med 2012 Mar 8;366(10):956-7

61) Guidelines for the use and interpretation of assays monitoring autophagy Klionsky D et al Autophagy 2012 Apr;8(4):445-544.

62) Cancer Chromosomal Instability: therapeutic and diagnostic challenges, Nicholas McGranahan Rebecca A. Burrell, David Endesfelder, Marco R. Novelli, and Charles Swanton EMBO Reports 2012 Jun 1;13(6):528-38

63) Inter and Intratumour heterogeneity: a barrier to individualised medical therapy in renal cell carcinoma? Rosalie Fisher, James Larkin and Charles Swanton Front Oncol. 2012;2:49. Epub 2012 May 18.

64) The centriolar satellite protein Cep131 is important for genome stability. Christopher J Staples, Katie N Myers, Ryan D DBeveridge, Abhijit A Patil, Alvin J X Lee, Charles Swanton, Michael Howell, Simon J Boulton, and Spencer J Collis Journal of Cell Science (2012) Oct 15;125(Pt 20):4770-9.

65)My Cancer Genome: A unified genomics and clinical trial portal. Charles Swanton commentary for Lancet Oncology in press 2012

66) Intratumour Heterogeneity: Evolution through space and time Charles Swanton (2012) Cancer Research Oct 1;72(19):4875-82.

67) Modelling the evolution of genetic instability during tumour progression. RuchiraDatta, Alice Gutteridge, Charles Swanton, Carlo C Maley, Trevor A Graham.(2013) Evolutionary Applications Jan;6(1):20-33..

68) Plasma-Derived Tumor DNA Analysis at Whole-GenomeResolution, Clinical Chemistry Charles Swanton (2013) Jan;59(1):6-8.

69) Cancer Heterogeneity and "The Struggle for Existence": Diagnostic and Analytical Challenges Stuart Horswell, Nik Matthews and Charles Swanton Cancer Letters (2013)Nov 1;340(2):220-6..

70) LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and preinvasive squamous cell carcinoma development Liwen L, Teixeira VH, Yuan Z, GrahamTA ,Endesfelder D, Nicholson A, Falzon M, Wright N, Kschischo M, Swanton C, Carroll B, Watt FM, George J, Jensen KB, Giangreco A, Janes SM. (2012) Journal of Pathology, Mar;229(4):608-20

71) Genomic Analyses to select patients for adjuvant chemotherapy: trials and tribulations. Weigelt B, Reis-Filho JS, Swanton C. (2012). Ann Oncol Sep;23suppl 10:x211-8.

72) Cancer heterogeneity: implications for targeted therapeutics Rosalie Fisher, LajosPusztai, and Charles Swanton(2013) British Journal of Cancer Feb 19;108(3):479-85.

73) Utility of prognostic genomic tests in breast cancer: IMPAKT 2012 Working Group Statement. Azim HA Jr, Michiels S, Zagouri F, Delaloge S, Filipits M, Namer M, Neven P, Symmans WF, Thompson A, André F, Loi S, Swanton C.(2013) Annals of Oncology Mar;24(3):647-54.

74) Prognostic and Predictive Markers in Metastatic Renal Cell Carcinoma. Khattak MA, Bakr F, Krzystanek M, Szallasi Z, Gerlinger M, Santos C, Swanton C, Pickering LM, Gore ME, Larkin JM. J ClinOncol(2013)Mar 1;31(7):971-2.

75) The CIN4 chromosomal instability qPCR classifier defines tumor aneuploidy and stratifies outcome in grade 2 breast cancer Szász, A. Marcell, Li Q, Eklund A, Sztupinszki Z, Rowan A, Tőkés, A-MSzékely B, Kiss A, Szendrői M, GyőrffyB, Szállási Z*, Swanton C*, Kulka J*(2013) PLOS One 8(2):e56707.*corresponding authors

76)A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade 2, ER-positive breast cancers into low and high risk prognostic categories, Szekely B, Iwamoto T, Szasz AM, Qi Y, Matsuoka J, Symmans WF, Tokes AM, Kulka J, Swanton C, Pusztai L. (2013)Breast Cancer Res Treat. 2013 Apr;138(3):691-8.

77) Replication stress links cancer structural and numerical chromosomal instability Rebecca A. Burrell, Sarah E. McClelland, David Endesfelder, Petra Groth, Marie-Christine Weller, NadeemShaikh, Enric Domingo, NnennayaKanu, Sally M. Dewhurst, Eva Gronroos, Su Kit Chew, Andrew J. Rowan, Arne Schenk, Michal Sheffer, Michael Howell, MaikKschischo, Axel Behrens, Thomas Helleday ,Jiri Bartek, Ian P. Tomlinson, Charles Swanton* *corresponding author. (2013) NatureFeb 28;494(7438):492-6.

Accompanying News and Views Cancer: Stress mixes chromosomes. Janssen A, Medema RH. Nature. 2013 Feb 28;494(7438):439-41.

78) Tumour heterogeneity and immune-modulation Mariam Jamal-Hanjani, EiriniThanopoulou, Karl S Peggs, Sergio A Quezada and Charles Swanton, (2013) Current Opinion in PharmacologyAug;13(4):497-503

79)Taxane benefit in breast cancer—a role for grade and chromosomal stability Roger P. A’Hern, Mariam Jamal-Hanjani, A. MarcellSzász, Stephen R. D. Johnston, Jorge S. Reis-Filho, Rebecca Roylance andCharles Swanton* *corresponding author (2013) Nature Reviews Clinical Oncology 2013 May 7. doi: 10.1038/nrclinonc.2013.67..

80)Parallel evolution of tumor subclones mimics diversity between tumorsPierre Martinez, Nicolai JuulBirkbak, Marco Gerlinger, Nicholas McGranahan, Rebecca Burrell, Andrew Rowan, Tejal Joshi, Rosalie Fisher, James Larkin, ZoltanSzallasi, Charles Swanton* *corresponding author (2013) Journal of PathologyAug;230(4):356-64.

81) Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial. Moorcraft SY, Chau I, Peckitt C, Cunningham D, Rao S, Yim KL, Walther A, Jackson CG, Stamp G, Webb J, Smith G, Gillbanks A, Swanton C. Invest New Drugs. 2013 Oct;31(5):1339-44

82) Molecular profiling and the reclassification of cancer: divide and conquer. Munoz J, Swanton C, Kurzrock R. Am SocClinOncolEduc Book. (2013) 2013:127-34.

83) Adapting clinical paradigms to the challenges of cancer clonal evolution. Murugaesu N, Chew SK, Swanton C. Am J Pathol. 2013 Jun;182(6):

84) The causes and consequences of genetic heterogeneity in cancer evolution. Burrell RA, Mcgranahan N, Bartek J, Swanton C Nature (2013)Sep 19;501(7467):338-45.

85) HELQ promotes RAD51 paralog-dependent repair to avert germ cell attrition and tumorigenesisCarrieAdelman ,Rafal Lolo , KalindiParmer , Valerie Borel , KenichiroMatsuzaki , John Skehel , Gordon Stamp , Alan D'Andrea , Alessandro Sartori , Olga Murina , Nicolai Birkbak , ZuzanaHorejsi, Charles Swanton, Simon BoultonNature (2013) Oct 17;502(7471):381-4.

86) Implications of Intratumour Heterogeneity for Treatment Stratification Andrew Crockford, James Hicks and Charles Swanton Journal of Pathology (2014) Jan;232(2):264-73.

87) Ultra-deep T-cell receptor sequencing reveals the complexity and intratumour heterogeneity of T-cell clones in renal cell carcinomas. Marco Gerlinger, Sergio A. Quezada, Karl S. Peggs, Andrew J.S. Furness, Rosalie Fisher, Teresa Marafioti, Vishvesh H. Shende5, Nicholas McGranahan, Andrew J. Rowan, Steven Hazell, David Hamm, Harlan S. Robins, Lisa Pickering, Martin

Gore, David L. Nicol, James Larkin, Charles Swanton Journal of Pathology (2013) Dec;231(4):424-32

88) Computation Optimisation of Targeted DNA Sequencing for Cancer DetectionPierre Martinez, Nicholas McGranahan, Nicolai JuulBirkbak, Marco Gerlinger, and Charles SwantonScientific Reports (2013)Dec 3;3:3309.

89) A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.Hudis C, Swanton C,Janjigian YY, Lee R, Sutherland S, Lehman R, Chandarlapaty S, Hamilton N, Gajria D, Knowles J, Shah J, Shannon K, Tetteh E, Sullivan DM, Moreno C, Yan L, Han HS. Breast Cancer Res. 2013 Nov 19;15(6):R110

90) Tolerance of whole genome doubling propagates chromosomal instability and accelerates cancer genome evolutionSally M Dewhurst & Nicholas McGranahan, Rebecca A Burrell, Andrew J Rowan, Eva Grönroos, David Endesfelder, Tejal Joshi, Dmitri Mouradov, Peter Gibbs, Robyn L. Ward, Nicholas J. Hawkins, ZoltanSzallasi, Oliver M. Sieber& Charles Swanton Cancer Discovery(2014)Feb;4(2):175-85.

91)The evolution of the unstable cancer genome Rebecca A Burrell and Charles Swanton Current Opinion in Genetics and Development(2014) in press

92) The genomic architecture and evolution of clear cell renal cell carcinomas defined by multi-region sequencingM Gerlinger*, S Horswell*, J Larkin*, AJ Rowan*, M Salm*, I Varela, R Fisher, N McGranahan, NMatthews, CR Santos, P Martinez, B Phillimore, S Begum, A Rabinowitz, B Spencer-Dene, S Gulati, PBates, G Stamp, L Pickering, M Gore, DL Nicol, S Hazell, PA Futreal, A Stewart, C SwantonNature Genetics (2014) Mar;46(3):225-33

Accompanying news and views:Intratumoral Heterogeneity in Kidney Cancer Ricketts CJ, Linehan WM, Nature Genetics 2014 Feb 26; 46(3);214-5

93) Cancer Evolution: The Final Frontier of Precision Medicine?Charles Swanton Annals of Oncology(2014)Mar;25(3):549-51

94) SAFIR01: Steps Towards Precision Breast Cancer MedicineCharles Swanton Lancet Oncology(2014)Mar;15(3):242-3

95) Predictive performance of microarray gene signatures: impact of tumor heterogeneity and multiple mechanisms of drug resistance (2014) Cancer Research in press

96) Ccdc13; a novel human centriolar satellite protein required for ciliogenesis and genome stability. Christopher J Staples, Katie N Myers, Ryan D. D. Beveridge, Abhijit A Patil, Anna E Howard, Giancarlo Barone, Alvin J. X. Lee, Charles Swanton, Michael Howell, Sarah Maslen, Mark J. Skehel, Simon J. Boulton, and Spencer J Collis Journal of Cell Science (2014) May 9th

97) Chromosomal instability selects gene copy number variants encoding core regulators of proliferation in ER+ breast cancerCancer Research (2014) Endesfelder D, Burrell R, Kanu N, McGranahan N, Howell M, Parker PJ, Downward J, Swanton C*, Kschischo M*. *Joint Corresponding AuthorsCancer ResearchJun 26.

98)Tumour Heterogeneity and the Evolution of Polyclonal DrugResistance Molecular Oncology (2014) Rebecca Burrell and Charles Swanton

99)Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Carcinoma Biomarkers(2014) SakshiGulati, Paul Bates*, Charles Swanton* andMarco Gerlinger *Bates and Swanton joint Corresponding Authors European Urology Jul 18. pii: S0302-2838(14)00627-7

100)Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx StudyJamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C, Quezada S, Middleton G, de Bruin E, Le Quesne J, Shafi S, Falzon M, Horswell S, Blackhall F, Khan I, Janes S, Nicolson M, Lawrence D, Forster M, Fennell D, Lee SM, Lester J, Kerr K, Muller S, Iles N, Smith S, Murugaesu N, Mitter R, Salm M, Stuart A, Matthews N, Adams H, Ahmad T, Attanoos R, Bennett J, Birkbak NJ, Booton R, Brady G, Buchan K, Capitano A, Chetty M, Cobbold M, Crosbie P, Davies H, Denison A, Djearman M, Goldman J, Haswell T, Joseph L, Kornaszewska M, Krebs M, Langman G, MacKenzie M, Millar J, Morgan B, Naidu B, Nonaka D, Peggs K, Pritchard C, Remmen H, Rowan A, Shah R, Smith E, Summers Y, Taylor M, Veeriah S, Waller D, Wilcox B, Wilcox M, Woolhouse I, McGranahan N,Swanton C. PLOS Biology (2014)Jul 8;12(7)

101) Chromosomal instability, aneuploidy, and cancer.Bakhoum SF, Swanton C. Front Oncol. 2014 Jun 19;4

102) Combined inhibition of BRAF and MEK in melanoma patients. Jeff Infante and Charles SwantonLancet Oncology (2014) July 15

103)Spatial and temporal diversity in genomic instability processes defines lung cancer evolution(2014) Elza C. de Bruin, Nicholas McGranahan, Richard Mitter, Max Salm, David C. Wedge, Lucy Yates, Mariam Jamal-Hanjani, SeemaShafi, NirupaMurugaesu, Andrew J. Rowan, Eva Gronroos,Madiha Anwar Muhammad, Stuart Horswell, Marco Gerlinger, Ignacio Varela, David Jones, John Marshall, Thierry Voet, Peter Van Loo, Doris M Rassl, Robert C Rintoul, Sam M. Janes, Siow-Ming Lee, Martin Forster, Tanya Ahmed, David Lawrence, Mary Falzon, ArrigoCapitanio, Timothy T. Harkins, Clarence C. Lee, Warren Tom, EnockTeefe, Shann-Ching Chen, Sharmin Begum, Adam Rabinowitz, Benjamin Phillimore, Bradley Spencer-Dene, Gordon Stamp, ZoltanSzallasi, Nik Matthews, Aengus Stewart, Peter Campbell, Charles SwantonScience (2014) Oct 10;346(6206):251-6

Accompanying news and views:

104) Development of synchronous VHL syndrome tumors reveals contingencies andconstraints to tumor evolution (2014) Rosalie Fisher, Stuart Horswell, Andrew Rowan, Max Salm, Elza De Bruin, Marco Gerlinger, NicholasMcGranahan, Ignacio Varela, Andrew Crockford, Francesco Favero, VirginieQuidville, Fabrice André, Carolina Navas, Eva Grönroos, David Nicol, Steve Hazell, David Hrouda, Tim O’Brien, Nik Matthews, Ben Phillimore, Sharmin Begum, SakshiGulati, Paul A. Bates, Neil Q. McDonald, Lisa Pickering, Martin Gore, James Larkin and Charles SwantonGenome Biology*Aug 27;15(8):433.

105) 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients.Gaykema SB, Schröder CP, Vitfell-Rasmussen J, Chua S, Oude Munnink TH, Brouwers AH, Bongaerts AH, Akimov M, Fernandez-Ibarra C, Lub-de Hooge MN, de Vries EG, Swanton C, Banerji U.Clin Cancer Res. 2014 Aug 1;20(15):3945-54

106) Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine.Crispin Hiley, Elza C de Bruin, Nicholas McGranahan, and Charles Swanton Genome Biology2014 Aug 27;15(8):453.

107) Multidisciplinary urological engagement in translational renal cancer research.Stewart GD, Harrison DJ, Swanton C, Lewis R, Bliss J, Larkin J, Nicol DL; A‐PREDICT TMG. BJU Int 2014 Feb 21

108) The Genome of the Chicken DT40 Bursal Lymphoma Cell Line.JánosMolnár,ÁdámPóti,OrsolyaPipek,MarcinKrzystanek,NnennayaKanu,Charles Swanton,Gábor E. Tusnády,ZoltánSzállási,IstvánCsabaiand DávidSzüts Genes Genomes Genetics (2014)

109) Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer.Roylance R, Endesfelder D, Jamal-Hanjani M, Burrell RA, Gorman P, Sander J, Murphy N, Birkbak NJ, Hanby AM, Speirs V, Johnston SR, Kschischo M, Swanton C.Breast Cancer Res Treat. 2014 Oct 7. [Epub ahead of print]

110) Deciphering clonality in aneuploidtumors using SNP array and sequencing dataIngrid M Lönnstedt, Franco Caramia, Jason Li, Debora Fumagalli, Roberto Salgado, Andrew Rowan, Max Salm, NnennayaKanu, Peter Savas, Stuart Horswell5, Stephan Gade, SibylleLoibl, Patrick Neven, Christos Sotiriou, Charles Swanton,ShereneLoi and Terence P Speed Genome Biology (2014) Oct 1;15(9):470

111) Spatial and temporal cancer evolution: causes and consequencese of tumour diversity.(2014) Hiley CT and Swanton CClin Med Dec 2014 suppl 6:s33-7

112) Cancer: Evolution Within a Lifetime.Gerlinger M, McGranahan N, Dewhurst SM, Burrell RA, Tomlinson I, Swanton C.Annu Rev Genet. 2014 Oct 1.

113)Epigenetic Noise Fuels Cancer Evolution (2014) Charles Swanton and Stephan Beck Cancer CellDec 8;26(6):775-6

114) SETD2 loss of function promotes renal cancer branched evolution through replication stress and impaired DNA repair (2015) Kanu N., Gronroos E, Martinez P., Burrell RA,et al. Bartek J and Swanton C Oncogene accepted in press

115) Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macroevolution of a double minute chromosome (2015), Favero F, Mcgranahan N., Birkbak N, et al Annals of Oncology

116) Translational implications of tumor heterogeneityJamal-Hanjani M, Larkin J, Quezada S and Swanton C. (2015) Clinical Cancer Research Mar 15;21(6):1258-1266

117) Can oncology recapitulate paleontology? Lessons from species extinctionsViola Walther, Crispin Hiley, Darryl Shibata, Charles Swanton, Paul Turner, and Carlo Maley Nature Reviews Clinical Oncology (2015)February 17accepted in press

118) Biological and therapeutic impact of intratumour heterogeneity in cancer evolution (2015) Nicholas Mcgranahan and Charles Swanton Cancer Cell Jan 12;27(1):15-26

119) Mutation Order Constrains Cancer Evolution (2015) Charles Swanton New England Journal of MedicineFeb 12;372(7):661-663

120) Recurrent chromosomal gains and heterogeneous driver mutations characterise Papillary Renal Cell Carcinoma evolution(2015), Michal Kovac, Chiara Bardella, Francesc Castro-Giner, Maggie Gorman, Jennet Williams, Emma Jaeger, Angela Jones, Kimberley Howarth, Carolina Navas, Stuart Horswell, Maximilian Salm, Andrew Rowan, Rosalie Fisher, Mark Stares, Gordon Stamp, Nik Matthews, Ben Phillimore, Sharmin Begum, Adam Rabinowitz, Charles Swanton, Monika Kováčová, Elza de Bruin, James Larkin, Lisa Pickering, Martin Gore, David Nicol, Steve Hazell, Tim O'Brien, Ben Challacombe, Ignacio Varela, Ashish Chandra, Catherine Horsfield, Alexander Polson, Luigi Terracciano, SerenellaEppenberger-Castori, Karl Heinimann, Andrew Protheroe, Peter Ratcliffe, Eamonn Maher, Rupesh Bhatt, Mona El-Bahrawy, Stewart Fleming, Seiko Makino, and Maxine Tran, Charles Swanton* and Ian Tomlinson*Nature Communications 2015 Mar 19;6:6336.* Joint corresponding authors

121) Managing Breast Cancer Tumour Heterogeneity Nature Reviews Clinical Oncology in press (2015) in press

122) New approaches for improving outcomes in breast cancer in Europe.Di Leo A, Curigliano G, Diéras V, Malorni L, Sotiriou C, Swanton C, Thompson A, Tutt A, Piccart M. (2015)Breast. Mar 31.

123) Inferring mutational timing and reconstructing tumour evolutionary histories.Turajlic S, McGranahan N, Swanton C.(2015)BiochimBiophysActa.2015 Mar 27.pii: S0304-419X(15)00020-7

124) Clonal status of actionable driver events and the timing of mutational processes in cancer evolution (2015) Nicholas McGranahan, Francesco Favero, Elza C. de Bruin4, Nicolai JuulBirkbak, ZoltanSzallasi,Charles Swanton Science Translational MedicineApril 17th

Books and Book Chapters

1) Cancer Biology and Treatment: A Molecular and Therapeutic Overview (2011) Minchom A., Starling N., Swanton C.2) Oncology An Evidence Based Approach : Editors Chang, Ganz, Hayes et al.. Springer (2006) p73-91.Principles of Targeted and Biological Therapies. S. Johnston, S. Chua and C. Swanton3) Metastatic Breast Cancer Handbook 1st edition. Published July 2006 Taylor and Francis : Edited by S. Johnston and C. Swanton 4) Metastatic Breast Cancer Handbook. Published July 2006 Taylor and Francis : chapter: Introduction and Chemotherapy and Metastatic Breast Cancer p33-61 C. Swanton 5) Metastatic Breast Cancer Handbook. 2nd Edition to be Published December 2011 Taylor and Francis : Edited by S. Johnston and C. Swanton

Good Clinical Practice, Management and Communication Skills Training

GCP course RMH December 2005 GCP refresher course RMH October 2008 GCP refresher course RMH June 2011 GCP refresher course UCL Sept 2013 PASTEST Management Course Sept 2007 Advanced communication skills course June 2011 Equality and Diversity Training March 2010 Supervision training February 2010

Cancer Clinical Trial Responsibilities

Chief Investigator Bolero 1 Phase III HER2+ metastatic breast cancer clinical trial

Chief Investigator MK2206+Trastuzumab and Lapatinib Phase I clinical trial in HER2+ metastatic breast cancer

Chief Investigator AZD8931+Paclitaxel in Her2 low advanced breast cancer

Co-investigator Phase I clinical trial of Abiraterone Acetate in ER+ and AR+ breast cancer.

Principal Investigator Phase II clinical trial of Abiraterone Acetate in ER+ and AR+ breast cancer.

TOPARP ICR-CTSU Metastatic Castration resistant prostate cancer trial steering committee member

MYPATHWAY Stratified Medicine GENENTECH Clinical trial steering committee member

MATRIX Stratified Medicine CRUK Clinical trial steering committee member

Chief Investigator TRACERx Longitudinal Cancer Evolution Study

Peer Reviewing Activities

International Journal of Cancer, Lancet Oncology, Nature Cell BiologyNature, New England Journal of Medicine, Journal of Biology, Breast Cancer Campaign, Austrian Science Fund, AICR, Irish Research Board, BMC GenomicsMolecular Cancer Therapeutics, Cancer Biology and Therapy, Cancer Research, Clinical Cancer Research, Embo Reports, Lancet, Science.

Date Committees, Editorial and Advisory Boards2005-2012 Member RNAi Global2006-2010 Expert panel member, South West London Local Research

Ethics Committee.2006-present

Member, UCL MBPhD appointments panel.2009-present

Sage Bionetworks consortium member and Sage Governance Group Committee member

2009-present

ESMO/ECCO Scientific advisory board panel member2010-present

Metastatic Breast Cancer Forum: Editorial Advisory Board Member

2010-present

Biotherapy Development Association: Advisory Board Member

2010-present

CR-UK Stratified Medicines Technology Advisory Group member

2010 NICE-Health Technology Appraisal Briefing for use of Adjuvant Zoledronic Acid in Primary Breast Cancer

2010 NCRI CTRad Signal Transduction Workshop2010 European Association for Predictive, Preventive

&Personalised Medicine UK Board Member2011 Editorial Board EPMA Journal (European Association for

Predictive, Preventive &Personalised Medicine).2011-2012 Cancer Research UK Biomarkers and Imaging Discovery

and Development (BIDD) Committee member2011 European Union Framework Program 8 Advisory Board

Member

2011-3 IMPAKT-ESMO Conference Scientific Advisory Board member

2011 Cancer Research UK Biomarkers and Imaging Discovery and Development (BIDD) Genomics Grant Review Committee member

2011-present

Editorial Board Frontiers in Urological Oncology2011-2012 IMPAKT 2012 Taskforce Chair: Utility of Prognostic Genomic

Signatures in Breast Cancer Clinical Practice2011-12 Invited Visiting Professor Cedars Sinai Medical Centre Los

Angeles, USA2013 17th ECCO - 38th ESMO - 32nd ESTRO European Cancer

Congress: Chair Translational Research Session2013 17th ECCO - 38th ESMO - 32nd ESTRO European Cancer

Congress: Expert Lung cancer Session2012-13 Genome Canada’s 2012 Large-Scale Applied Research

Project Competition inGenomics and Personalized Health.  Expert Panel Grant Review Committee Member

2012-present

Editorial Board Journal of Pathology

2012-present

CR-UK Sciences Committee Vice Chair of Biomarkers Panel.2012 AACR-Kure It Grant for Kidney Cancer Research Scientific

Review Committee. Declined2012-present

Invasion, Metastasis, Angiogenesis, Hypoxia, Stem cells, for Campaign’s Breast Cancer Research Gap Analysis 2012 Committee member

2012-present

NCRI Lung Cancer Advanced Disease Clinical Studies Group2012-present

AACR-EORTC Molecular Targets and Therapeutics Conference 2013 scientific committee

2012-present

Deputy Chair of ESMO Translational Research Working Group

2013-present

Chair of Translational and Basic Science Track ESMO 20142013-present

Advisory Board for Department of Health Cancer Genomics Initiative

2013-present

Editorial Board Annals of Oncology

2013-present

Editorial Board BBA Reviews in Cancer

2014-present

Steering Committee for the GENENTECH My Pathway multi-arm stratified medicine Clinical trial

2014-present

Steering Committee for the CRUK MATRIX stratified medicine Clinical trial

2014 Vice Chair NCRI Conference 20142015 Chair NCRI Conference 20152014-present

Editorial Board Cold Spring Harbor Molecular Case Studies

Date Grants Awarded Amount1995 UCLMS. MBPhD Bursary £72,0002004 CR-UK Clinician Scientist Fellowship. Functional

Genomic RNAi Screens£750,000

2006 Novartis Educational Grant for CINATRA (Chromosomal Instability and Anti-Tubulin Response Assessment) EPO906, Phase II study

$400,000

2006 San Antonio Breast Cancer Symposium Basic Science Scholarship.

$2000

2006 TRICC Trans-TACT: 1 of 4 Lead Investigators Investigation of chromosomal instability in the TACT cohort and the role of spindle assembly checkpoint proteins in determining taxane sensitivity

£100,000

2008 SANOFI-AVENTIS : Neo-adjuvant docetaxel in primary breast cancer translational research

£70,000

2008-13

MRC Senior Clinical Research Fellowship £1.8 million

2008-14

CR-UK Senior Clinical Research Fellowship £2.2 million

2009 Translational research grant for Neo-adjuvant RAD001 clinical trial in renal cancer (co-applicant with Dr James Larkin): E-PREDICT

£210,000

2010 Inflammatory Breast Cancer UK £35,0002011-14

European Union Framework 7 PREDICT ConsortiumScientific Lead: Total €5,800000 funding Jan 2011-Jan 2014.

Swanton Laboratory€1,500,000

2011-13

Pfizer pre-operative clinical trial of Axitinib in renal cancer A-PREDICT: £150,000 for Translational research (co-applicant with Dr James Larkin)

2011-15

European Union Framework 7 RESPONSIFY ConsortiumTotal €700,000 funding Jan 2012-Jan 2015.

Swanton Laboratory€700,000

2011 Bayer Schering Pharma “Grants 4 Targets” Award for drug discovery work on MCT4 Renal Carcinoma target.

Swanton Laboratory€5000

2011-2013

Cancer Research UK BIDD Translational Grant Award for Multi-region Intratumour heterogeneity renal cancer sequencing program

Swanton Laboratory€100,000

2012-2015

Rosetrees Trust Intratumour heterogeneity and Next Generation Sequencing Research Award for the TRACERx trial.

Swanton Laboratory£50,000

2012-2015

The Rosetrees/Butterfield Trust Non Small Cell Lung Cancer Intratumour heterogeneity and Next

Swanton Laborato

Generation Sequencing Research Award for the TRACERx trial.

ry£390,000

2012-2014

The Prostate Cancer Foundation: Principal Investigator “Defining the clinical relevance of intratumour heterogeneity and subclonal evolution in prostate cancer”

$1million USD

2012- Breast Cancer Research Foundation Fellowship award

$237,000/yr

2014-2023

CR-UK TRACERxTRAcking lung Cancer Evolution through Therapy/Rx

£11.8 million

2014-2019

European Research Council Consolidator Grant THESEUS Program

€2 million

2014-2019

Rosetrees Clinical Research Fellowship £280,000

2013-2019

CR-UK Senior Group Leader Tenure 4 Core staffLab Consumables

2013-2019

MRC Bioinformatics Infrastructure Grant- co-Principal Applicant (Lead PI Jacky Pallas) with UCL/Francis Crick Institute

£6 million

2014 MRC Single Cell Genomics GrantCo-principal applicant UCL (Lead applicant Tariq Enver)

£3.55 million

2014-2019

MRC Imaging GrantCo-principal applicant (Lead applicant Mark Emberton)

2014-2019

MRC Grant for UK Genomic Medicine Infrastructure. Co-investigator

£24 million

Oral Presentations

Keynote/Plenary/Special Symposia lectures in Red

(D)= Declined

Date Presentation1997 DNA Tumour Virus Meeting, Cambridge, UK. “Viral Cyclin Evasion of Cyclin

Dependent Kinase Inhibitors”1997 Cell Cycle and Cancer Conference Kyoto,1998 “Viral Cyclin Evasion of Cyclin Dependent Kinase Inhibitors” Medical

Research Society, Royal College of Physicians. London UK2004 “Management of metastatic breast cancer” British Association of

Pharmacists, London, UK,2005 International Symposium: “Regeneration and Transformation in the

Pancreas” Germany , Cell Cycle Targeted Therapies : Pathways of least resistance.

2005 Plenary Session: “Large-scale RNA interference screens to investigate oncogenic signalling by Ras” Genome-wide RNAi Global Initiative Boston USA

2006 RNAi Global Consortium “Clinical Implications of an RNA interference screen” Amsterdam, Netherlands

2006 San Antonio Breast Cancer Symposium “A functional genomic screen implicates regulators of mitotic arrest and ceramide metabolism as determinants of sensitivity to paclitaxel and other chemotherapeutic drugs”

2007 Mitotic arrest and ceramide metabolism: Implications for drug sensitivity. Invited Oral Presentation Barts/London Research Institute Symposium. Staverton, UK.

2007 Mediators of mitotic arrest influence paclitaxel sensitivity Invited presentation Breakthrough Breast Cancer, Institute of Cancer Research, London, UK

2007 RNAi analysis of drug resistance pathways, Invited presentation Cambridge Research Institute, UK

2007 RNAi Functional Analysis of Drug Resistance Pathways, Invited presentation UCL Cancer Institute, London UK.

2007 A rational approach to microtubule targeted therapies in cancer based on functional genomic datasets. Invited presentation Semmelweis University Cancer Symposium, Budapest, Hungary.

2007 RNAi Functional Analysis of Drug Resistance Pathways, Invited presentation MRC Toxicology Unit, Leicester, UK.

2008 Identifying regulators of response to taxanes by RNA interference, Invited presentation Marie Curie Research Institute, Oxted, Surrey

2008 Microtubule Stabiliser Clinical Trial Development in Cancer Based on Functional Genomic Datasets, Microtubule and Cancer Meeting, Marseille, France.

2008 Functional Genomic Identification of CERT, a Ceramide Transporter, as a Regulator of Multidrug Sensitivity in Cancer. Glycolipid and Sphingolipid Biology, Invited presentation Gordon Research Conference, Tuscany, Italy.

2008 A rational approach to microtubule stabilizer clinical trial development based on functional genomic datasets. Invited presentationWorld Cancer Conference, Shanghai, July 2008

2008 Chromosomal Instability determines taxane sensitivity in vivo. Presentation NCRI conference Birmingham October 2008

2008 Exon array approaches to understanding of drug sensitivity pathways in cancer Invited presentation Affymetrix symposium NCRI conference October 2008

2008 CERT, functional genomic identification of a novel regulator of drug resistance. Invited presentation Medical Universitiy of South Carolina December 2008

2009 Synthetic lethal approaches to targeting drug resistance pathways in cancer Invited presentationInstitute of Molecular Pathology and Immunology at the University of Porto Cancer Modulation of programmed cell death and therapeutic targets in cancer and neurodegenerative diseases February 2009

2009 Functional genomic analysis of Taxane response pathways. Invited presentationMitosis and Cancer Symposium NetherlandsFebruary 2009

2009 Synthetic lethal approaches to targeting drug resistance in cancer. Invited Plenary Presentation Irish Association for Cancer Research March 2009

2009 Functional genomic identification of a predictive signature of Taxane and Carboplatin response in cancer, Invited presentation Merck Pharmaceuticals Philadelphia USA March 2009

2009 Combining Functional Genomics with Clinical Trial Design to Define Drug Sensitivity Mechanisms Invited presentation Astra Zeneca Science Day Royal Marsden Hospital London July 2009

2009 A Senior Oncologist’ view on Value Frameworks Invited Presentation Biotherapy Development Association Critical Success Factors for New Oncology Products Brussels September 2009

2009 Health Economic Value Frameworks and a Model to Drive Personalised

Therapeutics and Reduce QALY Costs Biotherapy Development Association Berlin September 2009

2009 Functional genomic and bioinformatics identification of pathways regulating chromosomal instability in cancer. Invited presentation Paterson research Institute Manchester UK September 2009

2010 Molecular Roles for the Multi-Drug Sensitiser CERT, a Mediator of Prognosis and Outcome in Breast Cancer. Invited Oral Presentation Glycolipid and Sphingolipid Gordon Research Conference San Francisco February 2010

2010 “Personalised medicines:  what is it, where do we stand & where are we going?” Genomics Approaches to Biomarker Development and Contribution to Personalised Cancer Therapeurics: A practical view from the field Invited Oral Presentation Personalised Medicines, DIA EuroMeeting, Monaco

2010 The Future of Oncology Drug Development: Invited presentationBDA Alpine Meeting Innsbruck March 2010

2010 Sage Congress Invited Presentation2010 Molecular Diagnostics for Cancer Drug Development Meeting - 22nd -23rd

June 2010, Boston Invited Presentation2010 EU Drug Development Workshop 10th June 2010 Invited Plenary Session

Presentation “Vision for Research on Stratification Biomarkers”2010 Personalised Medicine: Impacting Healthcare Harvard Medical

School November 2010 Invited Speaker for Keynote Lecture2010 Educational Symposium ESMO 2010 Sponsored by BoerhingerIngelheim:

Invited presentation “Mechanisms of HER2 targeted therapy resistance”

2010 Predictive biomarker research using RNA interference PREDICT: Invited plenary lecture RNAI Global Meeting London 2010

2011 Advancing Companion Diagnostic Development Conference Barcelona “The PREDICT Consortium: A partnership framework for biomarker discovery” January 2011Invited Speaker

2011 Molecular Mechanisms and Signalling in Cancer Biology Xiamen China, February 2011 Invited Speaker

2011 World Companion Diagnostics Summit “A Roadmap for Biomarker Discovery: A Multi-Disciplinary Approach” March 2011 Invited Speaker

2011 European Personalized Medicine & Diagnostics meeting “Challenges in Cancer Medicine Biomarker Discovery” March 2011 Invited Speaker

2011 Mechanisms of Cancer Drug Resistance: CR-UK/Ipatimup meeting Conference organiser and invited chair/speaker. Porto April 2011

2011 CNIO Frontiers Breast Cancer Meeting: Invited Speaker “Identification of Regulators of Drug Sensitivity and Chromosomal Instability in Cancer using Functional Genomics”

2011 Chair and Conference organiser XX Porto Drug Resistance Meeting Ipatimup“Chromosomal Instability : Causes and Consequences”

2011 “Mechanisms of Resistance to Tyrosine Kinase Inhibitors” Invited talk Kidney Cancer Association Meeting Warsaw, Poland May 2011

2011 ESMO/ECCO Advanced Breast Cancer Symposium: “Functional genomic approaches to the dissection of drug resistance mechanisms in breast cancer” Invited Speaker ESMO 26th September 2011

2011 ESMO/ECCO Advanced Breast Cancer Symposium: Invited Discussant Speaker ESMO 25th September 2011

2011 NCRI Parallel Session Chair: Cancer Drug Resistance November 20112012 ESMO/ECCO Invited Speaker RNAi and Drug resistance2012 ESMO/IMPAKT PLENARY KEYNOTE LECTURE:Intratumour

heterogeneity: A Challenge for Personalised Medicine2012 Invited speaker British Thoracic Oncology Group Intratumour

Heterogeneity and Drug Resistance (D)2012 AACR Invited Speaker Intratumour heterogeneity: A Challenge for

Personalised Medicine

2012 AACR invited Speaker EU Framework 7 Consortium: Biomarker Discovery in Cancer Research

2012 Invited Visiting Professor at Cedars Sinai Hospital2012 Invited speaker British Thoracic Oncology Group Intratumour

Heterogeneity and Drug Resistance2012 Invited speaker Sage Bionetworks-Ruijin Joint Symposium in Cancer

Research on Translational Medicine: Use of Biomarkers and Models of Disease

2012 2nd EACR-OECI Joint Training Course 'Molecular PATHOLOGY approach to cancer' Invited course speaker

2012 Invited speaker Institute of Cancer Research/Royal Marsden Hospital Personalised Medicine Conference.

2012 24th EORTC-NCI-AACR Symposium on ‘Molecular Targets and CancerTherapeutics’, Invited Speaker (D)

2012 NCRI Liverpool “Intratumour heterogeneity and drug resistance”2012 EMBO Molecular Medicine SphingolipidWorkshop: Invited Speaker October

2012 (D)2012 EORTC “Methodology of cancer clinical trials: The Next

Generation”, Brussels from 11 to 14 December 2012, faculty member and invited lecturer “Predict project, predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets” (D)

2012 Invited Speaker Institute Gustav Roussy “Intratumour Heterogeneity and Personalised Medicine”

2012 Cancer Induced Bone Disease invited speaker Chemoresistance and Tumour heterogeneity. (D)

2012 IV SOLTI Breast Cancer Research Group Scientific Meeting invited speaker2012 Invited Keynote lecture: Intratumour heterogeneity and

Personalised Medicine : Combating breast cancer meeting Munich November 23rd 2012(D)

2012 NKI/Netherlands Cancer Institute invited international speaker2012 Geoffrey Beene Symposium   Memorial Sloan-Kettering Cancer

Center “Cancer Heterogeneity”2012 NGS mini-symposium invited speaker “The Era of Next Generation

Sequencing in Cancer”2012 “Prestige Seminars” in Oncology: “Meet the Oncology Expert”.

Jules Bordet Institute, Brussels, Belgium2012 11th International Kidney Cancer Association Chicago October 2012

“The Challenge of Genetic Heterogeneity to RCC Translational Research”

2012 Renal Cancer 2013 invited speaker “Advancing targeted therapies in cancer”

2012 Insight on Genitourinary cancers Bari November 2012 “ Molecular Heterogeneity of RCC : Dilemma for treatment”

2012 11th International Consensus Meeting “Individualised Therapy of Primary Breast Cancer in the Light of Intrinsic Subtypes and Tumour Heterogeneity: Invited speaker Tumour Heterogeneity

2012 University of Gent Dept Medical Oncology 20th Anniversary lecture “Intratumour Heterogeneity”

2013 Institut Gustav Roussy First International Congress on Personalized Medicine and Targeted Therapies in Cancer (Dubai, United Arab Emirates) Invited Speaker (D)

2013 Invited Plenary NCRI: Intratumour heterogeneity and PersonalisedMedicine : November 3rd 2013

2013 Invited Speaker: Molecular based treatment of GI cancer 2013 (D)

2013 Invited Speaker Meeting of the German Society of Human Genetics “Individualized Tumor Characterization and Treatment”(D)

2013 CR-UK LRI and the Memorial Sloan-Kettering Cancer Institute Invited speaker May 2013

2012 Invited speakers Biomarkers in Drug Discovery & Development 2012 Berlin Germany Sept 10-11 (D)

2013 Invited speaker: International Symposium on Lung Cancer Leuven Belgium March 2013: “Intratumour heterogeneity between primary and metastatic sites”

2012 The Promise Of Personalised Medicines Conference. Royal Society 2012 Invited speaker

2013 Invited Speaker Mildred Scheel Cancer Conference, Bonn Germany

2013 2013 ESMO European Cancer Congress, Keynote Lecture “Tumour Heterogeneity” and impact on personalised medicine and clinical practice. Saturday  28th September 2013

2013 2013 AACR: Invited Speaker at Major Symposium, “The Ruth Sager Memorial Symposium: Cancer Heterogeneity"

2013 Inserm National Biobank Infrastructure Conference, France: Invited lecture on Tumour Heterogeneity

2013 Lorne Genomics Conference Australia: Invited lecture Intratumour Heterogeneity

2012 Sixth Belgian Symposium on theIntegration of Molecular Biology Advances into Oncology Clinical Practice “Cancer genome of solid tumors : How to deal clinically with these findings”

2013 Personalized Medicine in Silicon Valley Invited speaker. January 28-29 (D)

2013 Methods in Mammary Gland Biology and Breast Cancer' workshop in Weggis near Luzern, Switzerland: Invited Speaker Tumour Heterogeneity 25-27 April. (D)

2013 Keynote lecture: 16th International Symposium on Recent Advances in Drug Delivery Systems, February 3-6, 2013, Salt Lake City, Utah, USA. (D)

2013 Invited lecture 108th International Titisee Conference on “Causes and Consequences of Aneuploidy” to be held from October 23 - 27, 2013 in Titisee, Black Forest, Germany (D)

2013 Keynote SpeakerCambridge Healthtech Institute’s NGS for Drugs, Patients and Clinical Trials congress March 2013 in San Diego (D)

2012 BSMO-BORDET meeting Sixth Belgian Symposium on theIntegration of Molecular Biology Advances into Oncology Clinical Practice:Cancer genome of solid tumors : How to deal clinically with these findings November 2012

2013 Keynote Lecture Eurocancer Meeting June 25-26, 2013 (Palais des Congrès, Paris) on “INTRA-TUMOR HETEROGENEITY”.

2013 Keynote Lecture EORTC Annual Meeting (EGAM) “A new angle to system biology / intra-tumor heterogeneity”. March 7th 2013

2013 Plenary Session Lancet Oncology ASIA meeting Bangkok “INTRA-TUMOR HETEROGENEITY”. March 22 2013

2013 Plenary Session Controlled Release Symposium Annual Meeting Hawaii July 2013. (D)

2013 Co-Chair 2013 Markers in Cancer Meeting : A joint meeting by ASCO, EORTC and NCI. (D)

2013 Haematology and Oncology Targeted Therapies conference Sydney Plenary Speaker Sydney March 2013.

2013 Keynote Lecture Tuscon Cancer Symposium, Ventana Medical Systems, March 2013

2013 EACR Molecular Pathology Meeting Amsterdam May 2013 Invited Speaker (D)

2013 15th Milan Breast Cancer Conference invited speaker June 20th 2013 (D)

2013 Nature CNIO Cancer Symposium Madrid October 2013 “Frontiers in Tumour Heterogeneity and Plasticity” Invited lecture

2013 Fourth International Symposium on Adrenal Cancer (FISAC), “Tumour Heterogeneity” Invited Plenary lecture (D)

2013 5th Freiburg Symposium on Anticancer Drug Discovery: Invited presentation April 2013 “Challenges in identifying predictive biomarkers presented by intra- and intertumoral heterogeneity.” (D)

2013 Solid Tumour Plenary Session Invited Lecture “Intratumour Heterogeneity and Branched Evolution” Association for Molecular Pathology (D)

2013 IACR Keynote Lecture Intratumour Heterogeneity in Breast Cancer (D)

2013 Invited Lecture: “tumor heterogeneity and tumor cell evolution” The 18th

TJCC (Taiwan Joint Cancer Conference) in 13th-14th July in Taipei, Taiwan.2013 International Kidney Cancer Coalition - Conference 2013 invited lecture

(Patient Advocacy groups).2013 American Society for Clinical Oncology (ASCO) 2013 Educational Session

Tumour Heterogeneity2013 American Society for Clinical Oncology (ASCO) 2013 Invited Lecture

Special Session Cancer Heterogeneity Monday, June 3, 20132013 2013 Fall Society of Basic Urologic Research Meeting, Tennessee

Nov 14-17th Lelund Chung Lecture (D)2013 Presidential Symposium “Solid Tumour Heterogeneity”

German, Austrian and Swiss Societies for Hematology and Oncology October 2013

2013 Methods in Clinical Cancer Research, to be held in Flims (Switzerland) from Saturday 22 to Friday 28 June 2013.Invited Faculty (D)

2013 X Madrid Breast Cancer Conference Opening Lecture Tumor heterogeneity. A handicap for research in cancer

2013 15th IASLC World Conference on Lung Cancer,WCLC 2013 Conference, October 27 - 30, 2013 Sydney.Invited Plenary Speaker

2013 Royal Society Theo Murphy international Scientific Meeting 'Cell polarity in the Systems Medicine era: The next 10 years' 17thApril (D)

2013 Drug Discovery 2013 Manchester September 4thPlenary Session2013 Co-Chair “Plenary Session on Genomic Heterogeneity In Cancers -

Implications For Responsiveness” AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference Boston, Oct 2013 (D)

2013 Invited Speaker EACR Conference: 23rd Biennial Congress of the European Association for Cancer Research to be held in Munich next year (5 – 8 July 2014).

2014 Invited Speaker Cancer for the Fondation Ipsen, Chantilly, France April 2014 (D)

2013 IRCAN Institute for Cancer and Ageing, Nice) Launch meeting Plenary Lecture June 2013

2014 2014 Gordon Research Conference on Mutagenesis CHANGES TO THE GENETIC LANDSCAPE, FROM SINGLE NUCLEOTIDES TO ENTIRE GENOMES Invited lecture

2013 European Multidisciplinary Conference in Thoracic Oncology

Keynote Lecture, Lugano Switzerland May 20132013 ESMO/EORTC/NCI Markers in Cancer Meeting November 2013

Invited presentation on "Intratumoral heterogeneity: issues at diagnosis and with selective drug pressures".

2013 6th Annual Cancer Center Symposium sponsored by the Cancer Center at Beth Israel Deaconess Medical Center Hitting theTarget: Drug Resistance, Tumor Heterogeneity, and Targeted Therapy. Invited Speaker

2013 Jacques Monod conference” on the Cell Cycle invited speaker (D) October 2013

2013 Invited talk Global Network Conference on Translational Medicine & Annual Congress of the European Society for Translational Medicine (EUSTM-2013) in Mondorf, Luxembourg, 14-16 October 2013, (D)

2014 Invited talk Third Symposium on Translational Genomics", Natcher Conference Center, March 20-21, 2014 on the NIH campus in Bethesda, MD.

2013 Invited talk Third AACR International Conference on Frontiers in Basic Cancer Research Wednesday, September 18 to Sunday, September 22, 2013.

2013 4th Annual Meeting of the Society for Translational Oncology VU Medical Centre Cancer Centre Amsterdam October 2013

2014 2014 ASCO Genitourinary Cancers Symposium, Invited Speaker General Session

2013/4 AACR 2014 Educational Session Committee Member2013 The National Cancer Institute “ Tumor cell heterogeneity” December 2nd-

3rd, 2013 at Vanderbilt (Nashville , TN) invited speaker (D)2014 DFG Annual Symposium “From molecular mechanisms to cancer therapy”,

Villa La Collina, Italy May 15 to 18, 2014. Invited participant and speaker (D)

2013 Invited Speaker “Clonal Heterogeneity” Presidential Session, German, Austrian and Swiss Societies for Hematology and Oncology.Vienna

2014 Invited Speaker “Clonal Heterogeneity” Oncology at the Limits Meeting February 2014

2014 Invited Chair of Educational Symposium at AACR 20142014 EMBO Workshop “A Systems-Level View of Cytoskeletal Function",

Rehovot, Israel, October 27-31, 2014 (D)2014 Tumor Heterogeneity – Challenges for Cancer Treatment and Diagnosis

AACR round table meeting, invited speaker 2014 (D)2014 Invited Calloway Lectureship, Memorial Sloan-Kettering Cancer

Center February 20142014 Invited speaker British Thoracic Oncology Group NSCLC Intratumour

Heterogeneity 2014 Invited speaker Gordon Research Conference on Mutagenesis. Melia Golf

Vichy Catalan, Girona, Spain, June 20142014 Tumour seminar “Difficult questions in renal cancer research” World

Health Organisation/IARC/NCI invited speaker2014 Invited Speaker ICC conference Madrid Making Sense of Technology &

Cancer Heterogeneity2014 Breast Cancer Frontier Meeting Tokyo November 2014 Invited Speaker2014 Third Symposium on Translational Genomics National Cancer Institute

Bethesda March 20th 2014 Invited Speaker2014 Stanford Cancer Institute “Tumour Heterogeneity: Implications for

Targeted Therapies” Invited Keynote Speaker October 20142014 TAT March 2014 Invited Speaker2014 Invited Speaker 2014 EMBO|EMBL Symposium: Tumour microenvironment

and signalling 7–10 May 2014 Heidelberg, Germany (D)2014 Invited Speaker 15th International Meeting on Human Genome Variation

and Complex Genome Analysis, Belfast, Northern Ireland, from 17-19 September, 2014

2014 Invited Speaker Molecular Mechanisms  in Cancer, Royal Tropical Institute in Amsterdam,  The Netherlands November 13-14, 2014.

2014 Keynote lecture From Science to Treatment Innovation in Cancer’ on 11-12 September 2014 in Brussels (D)

2014 EACR Special Conference on Radiation Biology in Cancer in Essen, Germany, from 5-7 February, 2015 (D) Invited lecture

2014 “Molecular Clinical Oncology” Invited Speaker Torino on October 4-5, 2014 (D)

2014 Wellcome Trust Cancer Pharmacogenomics and Targeted Therapies conference - 17 - 19th of September 2014 Session Chair and Invited Speaker

2014 Daniel den Hoed Cancer Center 100 years October 28-29 2014 – Invited Speaker (D)

2014 Invitation EACR Conference Series Precision Medicine for Cancer 2015, Neumünster Abbey, Luxembourg - Invited Speaker

2014 11th Ipsen Cancer series meeting  onTumor Heterogeneity & Tumor Microenvironment in Mysore , India from Feb 26-March, 20I5 - invited speaker

2014 Invitation to deliver keynote speech at Edinburgh Oncology Course, 25 March 2015 (D)

2014 IARC/NCI Tumor Seminar on Renal Cancer - Autumn 2014 (D)2014 Invitation - Precision Medicine in Epilepsy - Sept 29-30, 2014 – Invited

Speaker (D)2014 Innovation in Breast Cancer Symposium, Madrid Feb 2015 invited

speaker (D)2014 DFG HinterzartenerKreisfürKrebsforschung: from molecular mechanisms to

cancer therapy - 15th–17th May (D)2014 RCP conference on clinical genomics – 2nd May (D)2014 Up Close and Personalized,  Prague 26-28th June, 2014 (D)2014 EACR 23rd biennial congress, 5-8 July, 2014 (D)2014 FTNLS symposium 'from science to treatment innovation in cancer', 11-

12th Sept, 2014 (D)2014 Marseille SIRIC symposium, 1st October, 2014 (D)2014 EORTC-NCI-AACR symposium on molecular targets and cancer

therapeutics, 18-21st Nov 20142014 Precursors to breast cancer and tumor evolution, 23-30th Jan 2015

Barbados (D)2014 EACR conference Radiation Biology and Cancer: From Molecular Responses

to the Clinic, 5-7th Feb, 2015 (D)2014 Plenary Lecture Novartis Lead Global XII Conference June 2014

“Tumour Heterogeneity and Cancer Evolution2014 Royal College of Physicians Goulstonian Lecture and Graham Bull Prize in

Clinical Sciences February 20142014 NCI Invited Speaker Intratumour Heterogeneity Bethesda USA March 20142014 Intratumour Heterogeneity: Is it Relevant in RCC? Invited Speaker Kidney

Cancer Society Meeting Dublin April 20142014 Invited Speaker at the Cancer Pharmacogenomics and Targeted Therapies

conference - 17 - 19th of September 20142014 Invited Speaker at MRC Genome Instability Centre Sussex, October 20142014 ESMO Invited Speaker October 2014 and Invited Discussant2014 Hong Kong Academy of Medicine, Hong Kong International Cancer

Congress (HKICC) Invited Plenary Speaker November 20142014 12th Breast Cancer frontier meeting Keynote Lecture Tokyo

November 20142014 CGC.nl meeting Cellular Signalling and Cancer Therapeutics Amsterdam

Invited Lecture November 20142014 NCRI Liverpool November 2014 Vice Chairman2015 Immunology and Cancer (IRIC) 9th International Symposium titled

“Molecular Targets in Cancer Genomics” Invited Speaker

2015 Cold Spring Harbor The Biology of Cancer: Microenvironment, Metastasis and Therapeutics Meeting May 2015 Invited Speaker

2015 Pezcoller Symposium, Trento, Italy. June 2015 invited speaker.2015 Plenary Lecture Korean Cancer Association June 18-19 2015 (D).2015 Plenary European Neuroendocrine Tumour Society Annual

Conference 12th March 20152015 5th EACR-OECI Joint Training Course “Molecular Pathology approach to

cancer” Amsterdam 11th – 13th May 2015 invited Faculty2015 Second CRCL Symposium that will take place in Lyon, France, at the

International Congress Centre, the 21st, 22nd and 23rd of September 20152015 Invited Lecture “Comparative Genomics” ENS Lyon France, January 20152015 Invited Visiting Professor February 2015, 100th anniversary of the

Daniel den Hoed Cancer Centre, Erasmus MC Cancer Institute, Erasmus University Medical Centre Rotterdam

2015 Novartis: Region Europe investigator meeting on breast cancer, 10-11th July, 2014 (D)

2015 St Gallen Breast Cancer Consensus Conference Invited Speaker Tumour Heterogeneity 2015 (D)

2015 Hong Kong Medical Research Council Invited Plenary Speaker Annual Conference January 2015

2015 Nature Medicine-Volkswagen Foundation Invited Faculty Cancer Genomics and Tumor Heterogeneity, a Herrenhausen Symposium, May 18-20th, 2015 Herrenhausen Palace Conference Centre in Hannover, Germany.

2015 AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapyinvited speaker and panelist Grand America Hotel Salt Lake City Utah June 2015

2015 14th Annual Koch Institute Cancer Research Symposium CANCER COMPLEXITY: heterogeneity in tumor progression and drug response Invited Speaker Boston June 2015

2015 4th International Symposium of the German Center for Lung Research (DZL) Invited speaker

2015 2ND MULTIDISCIPLINARY LUNG CANCER CONFERENCE Faculty member and Keynote Invited speaker, Singapore National Cancer Centre

2015 15th Tucson Ventana Symposium Invited Speaker, Tucson Arizona March 2015

2015 European Association of Urologists Plenary Session Talk “ What would Charles Darwin make of Renal cell carcinoma?” Madrid March 2015 (D)

2015 Keynote lecture Platform for Exchange of Expertise and Research (PEER) meeting in pancreatic cancer. Cellgene February 2015 (D)

2015 European Institute of Oncology Milan Breast Cancer Conference Faculty Member and Invited Speaker 2015 (D)

2015 Russian International Kidney Cancer Symposium, Kidney Cancer Association, "Histological and Molecular Heterogenety of Renal Cell Carcinoma" Invited lecture, Moscow March 2015 (D)

2015 Brazilian Society of Medical Oncology International Conference(Oct 29th - Nov 1st) in Foz do Iguazu Invited Speaker (D)

2015 Opening Keynote lecture at the Cold Spring Harbor Asia Meeting on Precision Biology and Medicine to be held in Suzhou, China, May 4-8 2015

2015 Opening Keynote lecture at Cancer Biology Conference Erasmus Medical Centre Rotterdam

2015 United European Gastroenterology conference, Barcelona 25 to 28 October 2015 Invited talk (D)

2015 “Tumor Heterogeneity”in the PRESIDENTIAL SESSION, The Spanish Society for Medical Oncologyon Thursday, October 29th 2015, at 12:40h am

InterestsI enjoy mountain biking, hill climbing, photography and travel.